维拉帕米盐酸盐纳米脂质体凝胶用于增生性瘢痕的疗效与皮肤渗透研究
该研究将维拉帕米盐酸盐(VHCl)制备为纳米脂质体(niosome)并嵌入硅凝胶,优化后包封率为71.62%、囊泡粒径180 nm,体外可持续释放VHCl达48 h;兔耳模型体内研究显示28天后增生性瘢痕直径从7 mm降至1.9 mm,提示该纳米脂质体凝胶可改善渗透性并增强长期治疗的安全性与疗效。
要点
- VHCl纳米脂质体优化后包封率71.62%,囊泡粒径180 nm,单分散分布。
- 冻干制剂嵌入硅凝胶后可持续释放VHCl达48 h,具有良好的触变流变学行为。
- 兔耳增生性瘢痕模型28天后瘢痕直径从7 mm降至1.9 mm。
核心结论
- VHCl负载纳米脂质体凝胶在兔耳模型中显示增强的疗效,并改善渗透性和长期治疗的安全性。
研究设计与样本
- 采用薄膜水化技术制备VHCl纳米脂质体(Span-40与胆固醇摩尔比7:3),优化后嵌入硅凝胶,进行体外释放、稳定性及兔耳模型体内研究。
主要发现
- 优化纳米脂质体包封率为71.62%,囊泡粒径180 nm,TEM下呈单分散、球形和不规则形态,室温和冷藏温度下稳定性良好达60天。
- 冻干制剂嵌入硅凝胶后具有最佳pH和触变流变学行为,VHCl持续释放达48 h。
- 兔耳模型体内研究显示28天后增生性瘢痕直径从7 mm降至1.9 mm。
临床怎么用
- VHCl纳米脂质体凝胶可能作为增生性瘢痕局部治疗的一种候选方案,但需进一步临床研究验证。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertrophic scars arising from abnormal wound healing after burns, trauma, or surgery present challenges for their effective treatment. Verapamil hydrochloride (VHCl), a calcium channel blocker primarily used in cardiovascular diseases, has been proposed as a niosomal gel for topical hypertrophic scar treatment. VHCL stimulates procollagenase synthesis, induces actin filament depolymerization, and reduces fibrous tissue production, thus making it a promising candidate for scar therapy. Prior to formulation, FT-IR spectroscopy was performed to assess drug and excipient compatibility. VHCl niosomes were prepared using the thin-film hydration technique with Span-40 and cholesterol in a 7:3 molar ratio. The characterization included entrapment efficiency (%EE), vesicle size, and surface morphology. Optimized niosomes were incorporated into a gel, and in in-vitro drug release and stability studies were conducted. An in-vivo study was conducted using a rabbit model to assess formulation efficacy. Optimized VHCl niosomal formulations with high entrapment efficiency (%EE) of 71.62 % and a small vesicle size of 180 nm were used for characterization, in-vitro and in-vivo evaluations. The vesicles displayed a monodisperse distribution, spherical and irregular morphology under TEM, and good stability for 60 days at room and refrigerated temperatures. The lyophilized formulation incorporated into the silicone gel exhibited optimal pH, thixotropic rheological behavior, and sustained VHCl release for up to 48 h. In-vivo studies on a rabbit ear model revealed enhanced efficacy, reducing hypertrophic scar diameter from 7 mm to 1.9 mm after 28 days. The combination of VHCl-loaded niosomal gels demonstrated improved permeation and synergistic effects, enhancing the safety and efficacy of long-term VHCl treatment.
引用
- Namdeo S, Vishwakarma M, Haider T, et al. Repurposing verapamil hydrochloride with niosomal gel technology: Enhanced efficacy and skin penetration in hypertrophic scars. Burns. 2025. PMID: 40424672. doi:10.1016/j.burns.2025.107552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。